Dietary Approach to Mild-to-moderate Psoriasis
NCT05644782 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82
Last updated 2026-01-12
Summary
Psoriasis is a systemic chronic inflammatory immune-mediated disease whose etiopathogenetic mechanisms involve genetic predisposition, and immunological and environmental factors. Its prevalence is about 3% in adults, and it is characterized by well-demarcated, erythematous plaques, covered by silvery-white scales, in elbows, knees, trunk, and scalp. However, psoriasis is far from being considered just a dermatologic condition because the cytokine's cascade, which lays behind its inflammatory and immune-mediated pathogenesis, can determine multiple systemic manifestations. In addition, several patients with psoriasis often complains of gastrointestinal (GI) symptoms. Therefore, authors focused their attention over the gut-skin axis and its possible pathogenetic and immunoregulatory role in psoriasis (i.e., altered gut barrier, increased blood concentration of gut microbiota-derived metabolites, systemic inflammation). In this context, several dietetic approaches (e.g., Mediterranean, low calories, protein-restricted, vegetarian diets, and gluten-free diet, GFD) have shown a certain efficacy in improve psoriasis cutaneous and systemic manifestations. In recent years, the existence of a wheat-related disorder in patients who do not suffer from CD or wheat allergy (WA) has been definitively ascertained and defined as Non-Celiac Wheat Sensitivity (NCWS). Its prevalence in the general population is unknown, but self-reported NCWS is around 10%. This condition is characterized by both GI and extraintestinal symptoms, which are triggered by wheat ingestion. In these patients, wheat ingestion might lead to alteration in intestinal permeability and gut microbiota and to systemic immune activation and inflammation. Based on the evidence of gut involvement in the pathogenesis and clinical manifestation of psoriasis, as well as on the ability of gluten/wheat to increase intestinal permeability, it could be hypothesized that gluten/wheat may represents one of the pathogenetic environmental factors of psoriasis and that its intake may be able to worsen symptoms in affected patients. The investigators hypothesize that a wheat-free diet (WFD) can reduce the inflammatory state and ameliorate the clinical symptoms in psoriasis patients. The successive clinical and immunologic reaction to the re-exposure to wheat ingestion, performed by an open challenge, will be also evaluated to confirm a wheat-dependent mechanism and to understand the underlining physiopathology.
Conditions
- Psoriasis
- Gluten Sensitivity
Interventions
- OTHER
-
Open wheat challenge
Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
- OTHER
-
Placebo challenge
Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
Sponsors & Collaborators
-
Aurelio Seidita
collaborator UNKNOWN -
University of Palermo
lead OTHER
Principal Investigators
-
Antonio Carroccio, MD · University of Palermo
-
Maria R. Bongiorno, MD · University of Palermo
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-01
- Primary Completion
- 2026-01-01
- Completion
- 2027-01-01
Countries
- Italy
Study Locations
More Related Trials
-
Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis
NCT03359577 ·Status: COMPLETED ·Phase: NA
-
Modified Intermittent Fasting in Psoriasis
NCT04418791 ·Status: COMPLETED ·Phase: NA
-
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
NCT02618616 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis
NCT05184699 ·Status: UNKNOWN ·Phase: NA
-
Dietary Perceptions and Practices in Chinese Psoriasis Patients
NCT05118425 ·Status: COMPLETED
-
Aggressive Weight Loss Program in Chronic Plaque Psoriasis
NCT03531528 ·Status: COMPLETED ·Phase: NA
-
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
NCT00678470 ·Status: COMPLETED ·Phase: NA
-
Systematic Review And Meta-Analysis Of Psoriasis Treatments.
NCT01425138 ·Status: COMPLETED
-
Impact of Clinical and Psychological Factors on Treatment Satisfaction in Psoriatic Patients in Biological Therapy
NCT06102356 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
NCT00601107 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis
NCT02271971 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372 ·Status: COMPLETED ·Phase: PHASE2
-
Climatotherapy Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis
NCT03156062 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis
NCT02191020 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
NCT06801821 ·Status: RECRUITING
-
Psoriasis Inflammation and Systemic Co Morbidities
NCT01170715 ·Status: COMPLETED ·Phase: NA
-
Natural Gels for Treatment of Plaque Psoriasis
NCT02330237 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Weight Loss on Psoriasis
NCT01137188 ·Status: COMPLETED ·Phase: NA
-
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
NCT02310750 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
NCT05268016 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
NCT02239666 ·Status: COMPLETED
-
Characterization of Cutaneous Microbiota in the Psoriasis Pathogenesis
NCT03475914 ·Status: COMPLETED
-
Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
NCT01147874 ·Status: COMPLETED ·Phase: PHASE4
-
Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
NCT00512187 ·Status: COMPLETED ·Phase: PHASE4
-
Improvement of Psoriasis Patients' Adherence to Topical Drugs
NCT04220554 ·Status: COMPLETED ·Phase: NA